A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.

Trial Details

NCT ID
NCT05955105
Phase
PHASE1 / PHASE2
Sponsor
Innolake Biopharm
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • ILB-2109
  • Toripalimab
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Adult patients between the ages of 18 and 80 years.
  • Patients with histologically or cytologically confirmed solid tumours that are advanced, metastatic and or progressive, for whom there is no effect…
  • Eastern Collaborative Oncology Group (ECOG) Performance Status of ≤2.
  • Expected life expectancy ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →